VIVUS (VVUS) Releases Earnings Results, Beats Expectations By $0.06 EPS

VIVUS (VVUS) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $-0.11 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.06. Analysts had a consensus of $-0.17. The company posted revenue of $13.77 million in the period, compared to analysts expectations of $16.50 million. The company’s revenue was down -40.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.19 EPS.

VIVUS closed down -0.0798 points or -7.60% at $0.9702 with 9,82,362 shares getting traded on Tusday. Post opening the session at $1.06, the shares hit an intraday low of $0.93 and an intraday high of $1.07 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.

In a different news, on Aug 2, 2016, Santosh T Varghese (Chief Medical Officer) sold 12,559 shares at $1.07 per share price. According to the SEC, on Apr 20, 2016, John L Slebir (SVP, Business Development & GC) sold 9,933 shares at $2.20 per share price. On Apr 20, 2016, Guy P Marsh (VP, US Operations & GM) sold 633 shares at $3.04 per share price, according to the Form-4 filing with the securities and exchange commission.

VIVUS Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA) which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company is also developing and has completed the Phase II studies of Qsymia for the indication of OSA and diabetes. Qsymia is available in over 42000 certified retail pharmacies across the country. STENDRA is also approved by the European Commission (EC) under the name SPEDRA for the treatment of ED in the Europe. As of September 18 2014 the FDA approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.


Leave a Reply

VIVUS - Is it time to Sell?

Top Brokerage Firms are advising their investors on VIVUS. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.